Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...
BioSpace4h
Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
STAT2h
Vertex pain pill dominates earnings call discussion
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...
Vertex Q4 revenue beats Street, guidance in line with consensus
Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Stocktwits on MSN4h
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...